Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Adrenergic neurotransmitter system transporter and receptor genes associated with atomoxetine response in attention-deficit hyperactivity disorder children.

Yang L, Qian Q, Liu L, Li H, Faraone SV, Wang Y.

J Neural Transm (Vienna). 2013 Jul;120(7):1127-33. doi: 10.1007/s00702-012-0955-z. Epub 2012 Dec 25.

PMID:
23266789
2.

A haplotype of the norepinephrine transporter (Net) gene Slc6a2 is associated with clinical response to atomoxetine in attention-deficit hyperactivity disorder (ADHD).

Ramoz N, Boni C, Downing AM, Close SL, Peters SL, Prokop AM, Allen AJ, Hamon M, Purper-Ouakil D, Gorwood P.

Neuropsychopharmacology. 2009 Aug;34(9):2135-42. doi: 10.1038/npp.2009.39. Epub 2009 Apr 22.

3.

Variants of Dopamine Beta Hydroxylase Gene Moderate Atomoxetine Response in Children with Attention-Deficit/Hyperactivity Disorder.

Fang Y, Ji N, Cao Q, Su Y, Chen M, Wang Y, Yang L.

J Child Adolesc Psychopharmacol. 2015 Oct;25(8):625-32. doi: 10.1089/cap.2014.0178. Epub 2015 Oct 8.

4.

Norepinephrine genes predict response time variability and methylphenidate-induced changes in neuropsychological function in attention deficit hyperactivity disorder.

Kim BN, Kim JW, Cummins TD, Bellgrove MA, Hawi Z, Hong SB, Yang YH, Kim HJ, Shin MS, Cho SC, Kim JH, Son JW, Shin YM, Chung US, Han DH.

J Clin Psychopharmacol. 2013 Jun;33(3):356-62. doi: 10.1097/JCP.0b013e31828f9fc3.

PMID:
23609393
5.

Norepinephrine transporter -3081(A/T) and alpha-2A-adrenergic receptor MspI polymorphisms are associated with cardiovascular side effects of OROS-methylphenidate treatment.

Cho SC, Kim BN, Cummins TD, Kim JW, Bellgrove MA.

J Psychopharmacol. 2012 Mar;26(3):380-9. doi: 10.1177/0269881111405356. Epub 2011 May 31.

PMID:
21628343
6.

Atomoxetine improved attention in children and adolescents with attention-deficit/hyperactivity disorder and dyslexia in a 16 week, acute, randomized, double-blind trial.

Wietecha L, Williams D, Shaywitz S, Shaywitz B, Hooper SR, Wigal SB, Dunn D, McBurnett K.

J Child Adolesc Psychopharmacol. 2013 Nov;23(9):605-13. doi: 10.1089/cap.2013.0054. Epub 2013 Nov 9.

7.

Changes of urine dihydroxyphenylglycol to norepinephrine ratio in children with attention-deficit hyperactivity disorder (ADHD) treated with atomoxetine.

Montoya A, Escobar R, García-Polavieja MJ, Lachno DR, Alda JÁ, Artigas J, Cardo E, García M, Gastaminza X, Gilaberte I.

J Child Neurol. 2011 Jan;26(1):31-6. doi: 10.1177/0883073810371981. Epub 2010 Jun 4.

PMID:
20525942
8.

Atomoxetine as an adjunct therapy in the treatment of co-morbid attention-deficit/hyperactivity disorder in children and adolescents with bipolar I or II disorder.

Chang K, Nayar D, Howe M, Rana M.

J Child Adolesc Psychopharmacol. 2009 Oct;19(5):547-51. doi: 10.1089/cap.2009.0030.

PMID:
19877979
9.

Efficacy and safety of atomoxetine for attention-deficit/hyperactivity disorder in children and adolescents-meta-analysis and meta-regression analysis.

Cheng JY, Chen RY, Ko JS, Ng EM.

Psychopharmacology (Berl). 2007 Oct;194(2):197-209. Epub 2007 Jun 16.

PMID:
17572882
10.
11.

Prospective, naturalistic, pilot study of open-label atomoxetine treatment in preschool children with attention-deficit/hyperactivity disorder.

Ghuman JK, Aman MG, Ghuman HS, Reichenbacher T, Gelenberg A, Wright R, Rice S, Fort C.

J Child Adolesc Psychopharmacol. 2009 Apr;19(2):155-66. doi: 10.1089/cap.2008.054.

12.

Atomoxetine for attention-deficit/hyperactivity disorder symptoms in children with pervasive developmental disorders: a pilot study.

Troost PW, Steenhuis MP, Tuynman-Qua HG, Kalverdijk LJ, Buitelaar JK, Minderaa RB, Hoekstra PJ.

J Child Adolesc Psychopharmacol. 2006 Oct;16(5):611-9.

PMID:
17069549
13.

[Atomoxetine for the treatment of attention-deficit/hyperactivity disorder].

Davids E, Gastpar M.

Fortschr Neurol Psychiatr. 2004 Oct;72(10):586-91. German.

PMID:
15472782
14.

[Atomoxetine: a new treatment for Attention Deficit/Hyperactivity Disorder (ADHD) in children and adolescents].

Purper-Ouakil D, Fourneret P, Wohl M, Rénéric JP.

Encephale. 2005 May-Jun;31(3):337-48. Review. French.

PMID:
16142049
15.

Efficacy and safety of lisdexamfetamine dimesylate and atomoxetine in the treatment of attention-deficit/hyperactivity disorder: a head-to-head, randomized, double-blind, phase IIIb study.

Dittmann RW, Cardo E, Nagy P, Anderson CS, Bloomfield R, Caballero B, Higgins N, Hodgkins P, Lyne A, Civil R, Coghill D.

CNS Drugs. 2013 Dec;27(12):1081-92.

16.

Reduced short interval cortical inhibition correlates with atomoxetine response in children with attention-deficit hyperactivity disorder (ADHD).

Chen TH, Wu SW, Welge JA, Dixon SG, Shahana N, Huddleston DA, Sarvis AR, Sallee FR, Gilbert DL.

J Child Neurol. 2014 Dec;29(12):1672-9. doi: 10.1177/0883073813513333. Epub 2014 Jan 10.

17.

Progress and promise of attention-deficit hyperactivity disorder pharmacogenetics.

Froehlich TE, McGough JJ, Stein MA.

CNS Drugs. 2010 Feb;24(2):99-117. doi: 10.2165/11530290-000000000-00000. Review.

18.

Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.

Quintana H, Cherlin EA, Duesenberg DA, Bangs ME, Ramsey JL, Feldman PD, Allen AJ, Kelsey DK.

Clin Ther. 2007 Jun;29(6):1168-77.

PMID:
17692731
19.

Atomoxetine versus placebo in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: a double-blind, randomized, multicenter trial in Germany.

Dittmann RW, Schacht A, Helsberg K, Schneider-Fresenius C, Lehmann M, Lehmkuhl G, Wehmeier PM.

J Child Adolesc Psychopharmacol. 2011 Apr;21(2):97-110. doi: 10.1089/cap.2009.0111. Epub 2011 Apr 13.

PMID:
21488751
20.

[The effectiveness of atomoxetine in children, adolescents, and adults with ADHD. A systematic overview].

Sevecke K, Battel S, Dittmann RW, Lehmkuhl G, Döpfner M.

Nervenarzt. 2006 Mar;77(3):294, 297-300, 302-4 passim. Review. German.

PMID:
16133434

Supplemental Content

Support Center